Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPF… HAYWARD, Calif.–(BUSINESS WIR...
Avidity Biosciences (RNA) announced that its board of directors has designated the close of business, Eastern Time, on February 12 as the record… Avidity Biosciences (RNA) announced that its boa...
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026;… One-year follow-up data from Phase 2 t...
IDEAYA Biosciences (IDYA) provided a business update including an overview of key corporate objectives for 2026. 2026 Corporate Objectives: Daro… IDEAYA Biosciences (IDYA) provided a business up...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond… HAYWARD, Calif.–(BUSINESS WIR...
The Colossal Foundation, the nonprofit arm of the science fiction-y Dallas startup, announced Wednesday it had secured an additional $50 million in funding, bringing its total purse to $100 million. T...
